Wondering what your next move should be in the market? BullTrends.com can help lead the way. For free access to our complete stock reports, take a few minutes to register with us by clicking this link: http://www.bulltrends.com/
Shares of WPX Energy closed down 9.99% on Tuesday making it one of the biggest decliners in the NYSE market. The stock a major advance in volume traded with about 16.1 million shares traded compared to an average of about 2.6 million shares. The drop came after the company announced on Monday that its fourth-quarter and full-year earnings would be affected by up $1.4 billion in pretax impairment charges.
Shares of GMCR closed up 7.65% on Tuesday with about 10.3 million shares traded. The stock soared to a new 52-week high of $120.24 during intra-day trading despite the fact that TreeHouse Foods Inc said on Tuesday it had sued Green Mountain Coffee Roasters Inc for allegedly attempting to illegally maintain a monopoly over the pods used in its new Keurig coffee brewers due to be released later this year. Green Mountain plans to launch the new hot-drink brewing system, called Keurig 2.0, in the fall.
Nutranomics closed down 10.68% on Tuesday with nearly 370,000 shares traded. The company had no significant news since late January when it highlightedthe Company's on-going expansion strategy with business partner UNO International Corp, a leading health and natural products distributor and the largest multi-level marketing (MLM) company in the Philippines.
Shares of Cellceutix Corporation closed down 8.16% on Tuesday and was one of the biggest decliners in the OTC market. The stock traded about 850,000 shares and had a significant volume boost compared to an average of 225,000 shares traded. Earlier this month, the company, a clinical stage biopharmaceutical company that’s developing innovative therapies in oncology, dermatology, and antibiotic applications, announced that the protocol for the Phase 2b trial of Brilacidin, Cellceutix's lead compound in a novel class of synthetic immunomodulatory antimicrobials known as defensin-mimetics, was sent to the U.S. Food and Drug Administration.
Disclosure: BullTrends.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.